Combination therapy for early-relapse DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- Your lymphoma came back within 12 months of your first treatment (R-CHOP) or never fully went away.
- You have at least one tumor that can be measured on a CT scan (1.5 cm for lymph nodes, 1 cm elsewhere).
- You are age 19 or older and able to give informed consent.
- You have adequate kidney, liver, and blood cell counts (your doctor will check this).
- You cannot have had polatuzumab vedotin or glofitamab before, and must not have active infections or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zanubrutinib) as a first treatment for older adults (70+) with a common type of lymphoma called DLBCL. The goal is to see if this approach is effective and well-tolerated without standard chemotherapy.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This study compares three different drug combinations for people with untreated DLBCL. One group gets a standard combination (pola-RCHP), another gets that plus a targeted pill (like orelabrutinib or venetoclax), and a third gets the standard chemo without the targeted antibody. The goal is to see which approach works best and is safest.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.